The optimal management of T1 high-grade bladder cancer
DOI:
https://doi.org/10.5489/cuaj.1194Abstract
Stage T1Hg bladder cancer should be considered an aggressive andpotentially lethal disease. The importance of initial re-resection to
identify unrecognized muscle-invasive disease is significant. Most
patients with high-risk disease are candidates for initial bladder salvage
with intravesical bacillus Calmette-Guerin vaccine for
immunotherapy, a procedure with a high survival rate; however,
failure of the procedure may result in a guarded prognosis. Even
after apparent success, patients should be informed of the risks of
the disease progressing to muscle-invasive or metastatic disease
and the need for vigilant monitoring. Despite optimal management,
a significant number of patients relapse or progress to invasive disease
requiring cystectomy. This review provides insight into the
optimal management of T1 high-grade bladder cancer.
Downloads
Downloads
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.